Integral Diagnostics (IDX) Stock Overview
A healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
IDX Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Integral Diagnostics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.08 |
| 52 Week High | AU$3.07 |
| 52 Week Low | AU$2.00 |
| Beta | 0.13 |
| 1 Month Change | -6.73% |
| 3 Month Change | -13.33% |
| 1 Year Change | -13.69% |
| 3 Year Change | -38.46% |
| 5 Year Change | -57.11% |
| Change since IPO | 13.66% |
Recent News & Updates
IDX: New Leadership And New Clinics Will Support Future Upside
Analysts have trimmed their price target for Integral Diagnostics to A$3.11 from A$3.12 as they factor in a slightly higher discount rate and marginally softer profit margin expectations, while keeping revenue growth assumptions and future P/E largely unchanged. What's in the News New Managing Director and CEO Jason Martinez is scheduled to commence on 6 August 2026, with current Managing Director and CEO Dr Ian Kadish staying on until then to support a smooth leadership transition (Key Developments).IDX: New Leadership And Clinic Expansion Will Support Future Upside
Analysts have maintained their fair value estimate for Integral Diagnostics at A$3.12 per share. This reflects unchanged views on the discount rate, revenue growth, profit margin and future P/E assumptions, and this stability has resulted in an unchanged price target.IDX: Merger Synergies And New Sites Will Drive Future Upside
Analysts have nudged their price target on Integral Diagnostics slightly lower to A$3.12 from A$3.13. This reflects minor adjustments to fair value estimates, discount rate assumptions and forward P/E expectations.IDX: Merger Synergies And New Sites Will Support Future Upside
Analysts have made a small upward adjustment to their price target for Integral Diagnostics, which now sits slightly higher in A$ terms. This reflects modest tweaks to their fair value, discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations.Recent updates
IDX: New Leadership And New Clinics Will Support Future Upside
Analysts have trimmed their price target for Integral Diagnostics to A$3.11 from A$3.12 as they factor in a slightly higher discount rate and marginally softer profit margin expectations, while keeping revenue growth assumptions and future P/E largely unchanged. What's in the News New Managing Director and CEO Jason Martinez is scheduled to commence on 6 August 2026, with current Managing Director and CEO Dr Ian Kadish staying on until then to support a smooth leadership transition (Key Developments).IDX: New Leadership And Clinic Expansion Will Support Future Upside
Analysts have maintained their fair value estimate for Integral Diagnostics at A$3.12 per share. This reflects unchanged views on the discount rate, revenue growth, profit margin and future P/E assumptions, and this stability has resulted in an unchanged price target.IDX: Merger Synergies And New Sites Will Drive Future Upside
Analysts have nudged their price target on Integral Diagnostics slightly lower to A$3.12 from A$3.13. This reflects minor adjustments to fair value estimates, discount rate assumptions and forward P/E expectations.IDX: Merger Synergies And New Sites Will Support Future Upside
Analysts have made a small upward adjustment to their price target for Integral Diagnostics, which now sits slightly higher in A$ terms. This reflects modest tweaks to their fair value, discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations.IDX: Inorganic Expansion And Merger Synergies Will Drive Future Upside
Analysts have trimmed their price target for Integral Diagnostics from around A$3.36 to about A$3.12, reflecting updated assumptions for slightly lower revenue growth, modestly softer profit margins and a reduced future P/E multiple. What's in the News Management is actively assessing M&A options and continuing to look at inorganic growth, alongside opening 3 new greenfield sites in the last quarter of the financial year in Eastwood Private Hospital (South Australia), Wangaratta (Victoria) and Maroochydore (Queensland), plus a relocation to a new facility in Launceston (Key Developments).Upgraded MRI Licensing And Merger Synergies Will Fuel Future Success
Despite a sharp reduction in projected revenue growth, the consensus future P/E multiple for Integral Diagnostics has contracted significantly, supporting a higher analyst price target of A$3.34. Valuation Changes Summary of Valuation Changes for Integral Diagnostics The Consensus Analyst Price Target has risen from A$3.12 to A$3.34.
Upgraded MRI Licensing And Merger Synergies Will Fuel Future Success
Synergies from the Capitol Health merger and regulation changes are expected to boost operating margins and revenue for Integral Diagnostics.Slammed 29% Integral Diagnostics Limited (ASX:IDX) Screens Well Here But There Might Be A Catch
Integral Diagnostics Limited ( ASX:IDX ) shareholders that were waiting for something to happen have been dealt a blow...Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being
Key Insights Integral Diagnostics will host its Annual General Meeting on 28th of November Total pay for CEO Ian Kadish...Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year
Integral Diagnostics Limited ( ASX:IDX ) has announced that on 4th of April, it will be paying a dividend ofA$0.025...These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?
While Integral Diagnostics Limited ( ASX:IDX ) might not be the most widely known stock at the moment, it saw...Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year
Integral Diagnostics Limited ( ASX:IDX ) has announced it will be reducing its dividend payable on the 4th of April to...Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate
Does the February share price for Integral Diagnostics Limited ( ASX:IDX ) reflect what it's really worth? Today, we...Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why
The performance at Integral Diagnostics Limited ( ASX:IDX ) has been quite strong recently and CEO Ian Kadish has...Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...Shareholder Returns
| IDX | AU Healthcare | AU Market | |
|---|---|---|---|
| 7D | -1.4% | 0.5% | 0.08% |
| 1Y | -13.7% | -12.5% | 3.1% |
Return vs Industry: IDX underperformed the Australian Healthcare industry which returned -12.5% over the past year.
Return vs Market: IDX underperformed the Australian Market which returned 3.1% over the past year.
Price Volatility
| IDX volatility | |
|---|---|
| IDX Average Weekly Movement | 4.4% |
| Healthcare Industry Average Movement | 6.5% |
| Market Average Movement | 10.4% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 4.4% |
Stable Share Price: IDX has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: IDX's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 3,000 | Ian Kadish | www.integraldiagnostics.com.au |
Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. The company offers magnetic resonance imaging, positron emission tomography, computed tomography mammography, interventional radiology, ultrasound, and radiography, such as x-ray and EOS. Integral Diagnostics Limited was founded in 1967 and is headquartered in Melbourne, Australia.
Integral Diagnostics Limited Fundamentals Summary
| IDX fundamental statistics | |
|---|---|
| Market cap | AU$774.78m |
| Earnings (TTM) | AU$14.03m |
| Revenue (TTM) | AU$767.82m |
Is IDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDX income statement (TTM) | |
|---|---|
| Revenue | AU$767.82m |
| Cost of Revenue | AU$525.98m |
| Gross Profit | AU$241.84m |
| Other Expenses | AU$227.82m |
| Earnings | AU$14.03m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 25, 2026
| Earnings per share (EPS) | 0.038 |
| Gross Margin | 31.50% |
| Net Profit Margin | 1.83% |
| Debt/Equity Ratio | 50.1% |
How did IDX perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/24 22:39 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Integral Diagnostics Limited is covered by 21 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Benjamin Brayshaw | Barrenjoey Markets Pty Limited |
| Thomas Yeo | Barrenjoey Markets Pty Limited |
| Saul Hadassin | Barrenjoey Markets Pty Limited |